CA7 (Carbonic Anhydrase VII) Drug Discovery Landscape & Assay Solutions
- By admin
- 07 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for CNS & Isoform-Selective Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CA7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CA7 Recombinant Protein (WT & Active-Site Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. Zinc-containing active site. |
View CA7 Products |
| Gene Delivery | CA7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. HEK293 expressed. |
View CA7 Products |
| Benchmark Ab | Anti-CA7 Recombinant Antibody Sequence-verified positive control for Western/IF validation. |
View CA7 Products |
| Validator | CA7 siRNA Set For knockdown verification and specificity confirmation. |
View CA7 Products |
| Selectivity Panel: CA2 | CA2 Recombinant Protein Cytosolic off-target isoform for selectivity counter-screening. |
View CA2 Products |
| Selectivity Panel: CA9 | CA9 Recombinant Protein (ECD) Transmembrane tumor-associated isoform for cross-reactivity assessment. |
View CA9 Products |
| Selectivity Panel: CA12 | CA12 Recombinant Protein For broad-spectrum carbonic anhydrase selectivity mapping and renal toxicity assessment. |
View CA12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-isoform selectivity (vs. CA1, CA2, CA9, CA12) | Ortholog Panel Available: Human CA1, CA2, CA7, CA9, CA12 proteins with >95% purity and sequence verified identity for side-by-side Ki determination. |
| Intracellular target engagement (CNS penetration) | CA7-Overexpressing Stable Cell Lines (via Lentivirus) for cellular uptake and permeability assays in relevant CNS models. |
| Resistance mechanism & SAR studies | Mutant recombinant proteins available for active-site variant screening. |
| Assay specificity & false positives | Validated siRNA included for target-specificity confirmation. |
Live CA7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of CA7 remains concentrated in neurological and pain indications, driven by its distinct cytosolic expression profile in the CNS. While the broader carbonic anhydrase field has been dominated by oncology-targeting transmembrane isoforms such as CA9 and CA12, CA7 is emerging as a selective target for neuropathic pain, epilepsy, and cerebral edema. The competitive landscape is currently shaped by small-molecule discovery programs seeking to circumvent the systemic toxicity profile of pan-carbonic anhydrase inhibitors. First-generation sulfonamide derivatives established proof-of-concept for CNS penetration, but next-generation R&D is focused on achieving sub-nanomolar isoform selectivity against the ubiquitously expressed CA1 and CA2 to avoid metabolic acidosis and hematological side effects. Structure-guided medicinal chemistry using coumarin and sulfonamide scaffolds aims to optimize both blood-brain barrier permeability and selectivity. The field offers first-mover opportunities in CNS indications with limited clinical-stage inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Specialty neurology biotechs, academic consortia | Neuropathic Pain, Epilepsy | Selectivity Assay (Need CA7 vs. CA2/CA9 homolog panel) |
| CNS-Penetrant Sulfonamides | Specialized CNS drug developers | Neuroinflammation, Glioblastoma | Cell-based uptake assays using CA7-expressing stable lines |
| Isoform-Selective Inhibitors | CNS-focused discovery programs | Neuroprotection, Cerebral Edema | Enzymatic Inhibition Assay (Need high-purity active WT & mutant CA7) |
| Topical/Localized Formulations | Dermatology/Pain focused firms | Local Neuropathy | Tissue penetration validation with high-purity protein standards |
Molecular Differentiation & Assay Strategy
For best-in-class CA7 drugs, the following differentiation criteria are critical:
- Affinity & Selectivity: Sub-nanomolar Ki for CA7 and at least 100-fold selectivity over CA2/CA1 to avoid renal toxicity and acidosis. Use a panel of human CA1, CA2, CA7, CA9, CA12 recombinant proteins for parallel Ki determination via stop-flow spectrophotometry or FRET-based esterase assays.
- BBB Permeability: Oral or subcutaneous delivery requires optimization of lipophilicity and efflux ratio. Use CA7-overexpressing stable cell lines to perform cellular uptake assays and target engagement studies with siRNA controls.
- Mechanism Validation: Determine competitive vs. non-competitive inhibition using SPR (surface plasmon resonance) or thermal shift assays. High-purity protein (>95%, endotoxin <1 EU/µg) ensures minimal false positives from aggregation.
- Safety & Off-target Profiling: Expand selectivity panel to include CA4, CA12, CA14 to exclude mitochondrial and renal liabilities. Use CA7 siRNA for phenotype rescue experiments to confirm on-target mechanism.